SecurityPSP / PowerShares Exchange-Trade Fund Trust (73935X195)
Institutional Owners9
Institutional Shares289,778
Institutional Value$ 3,508,000 USD

Institutional Stock Ownership and Shareholders

PowerShares Exchange-Trade Fund Trust (NYSE:PSP) has 9 institutional investors and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 289,778 shares. Largest shareholders include Arthur Zaske & Associates, LLC, Ntv Asset Management Llc, Hsbc Holdings Plc, Ladenburg Thalmann Financial Services Inc, MetLife Securities, Inc, Commonwealth Equity Services, Inc, WFG Advisors, LP, Integrated Wealth Counsel, Llc, and Citigroup Inc.
PowerShares Exchange-Trade Fund Trust (NYSE:PSP) ownership structure shows current positions in the company by institutions and funds, as well as latest changes in position size. Major shareholders can include individual investors, mutual funds, hedge funds, or institutions. The Schedule 13D indicates that the investor holds more than 5% of the company and intends to actively pursue a change in business strategy. Schedule 13G indicates a passive investment of over 5%. Green rows indicate new positions. Red rows indicate closed positions. Click the link icon to see the full transaction history.

File DateFormInvestor Opt Prev
Shares
Current
Shares
Change
(Percent)
Prev Value
($1000)
Current Value
($1000)
Change
(Percent)
2018-08-14 13F-HR UNITED CAPITAL FINANCIAL ADVISERS, LLC 20,146 0 -100.00 243 0 -100.00
2018-07-27 13F-HR Advisory Services Network, LLC 4,204 0 -100.00 51 0 -100.00
2018-08-08 13F-HR LINCOLN NATIONAL CORP 56,786 0 -100.00 684 0 -100.00
2018-08-14 13F-HR Resources Investment Advisors, Inc. 233 0 -100.00 3 0 -100.00
2018-08-10 13F-HR PNC FINANCIAL SERVICES GROUP, INC. 11,484 0 -100.00 137 0 -100.00
2018-08-13 13F-HR Global Retirement Partners, Llc 9,978 0 -100.00 120 0 -100.00
2018-07-13 13F-HR JUNCTURE WEALTH STRATEGIES, LLC 435,098 0 -100.00 5,239 0 -100.00
2018-07-19 13F-HR Carroll Financial Associates, Inc. 400 0 -100.00 4 0 -100.00
2018-08-16 13F-HR Feltz WealthPLAN Inc. 20,762 0 -100.00 250 0 -100.00
2018-08-06 13F-HR BRIGHTON JONES LLC 30,000 0 -100.00 361 0 -100.00
2018-08-09 13F-HR Gradient Investments LLC 270 0 -100.00 3 0 -100.00
2018-08-14 13F-HR LPL Financial LLC 196,515 0 -100.00 2,366 0 -100.00
2018-08-14 13F-HR Parallax Volatility Advisers, L.P. 1 0 -100.00 0 0
2018-08-14 13F-HR UBS Group AG 82,386 0 -100.00 992 0 -100.00
2018-07-30 13F-HR Raymond James Financial Services Advisors, Inc. 32,842 0 -100.00 395 0 -100.00
2018-02-14 13F-HR Arthur Zaske & Associates, LLC 81,076 81,076 0.00 1,027 1,009 -1.75
2017-02-06 13F-HR INTEGRATED WEALTH COUNSEL, LLC 5,370 5,370 0.00 58 60 3.45
2018-08-14 13F-HR SUSQUEHANNA INTERNATIONAL GROUP, LLP 103,907 0 -100.00 1,251 0 -100.00
2018-08-08 13F-HR CIBC World Markets Inc. 35,361 0 -100.00 426 0 -100.00
2018-08-10 13F-HR NORTHWESTERN MUTUAL WEALTH MANAGEMENT CO 2,441 0 -100.00 29 0 -100.00
2018-08-14 13F-HR FIFTH THIRD BANCORP 37,060 0 -100.00 446 0 -100.00
2018-08-13 13F-HR Betterment LLC 38,383 0 -100.00 468 0 -100.00
2018-02-08 13F-HR GIRARD SECURITIES, INC. 20,348 0 -100.00 258 0 -100.00
2018-08-13 13F-HR BLAIR WILLIAM & CO/IL 83 0 -100.00 1 0 -100.00
2018-08-14 13F-HR COLONY GROUP LLC 22,917 0 -100.00 276 0 -100.00
2018-02-16 13F-HR/A Commonwealth Equity Services, Inc 14,015 15,089 7.66 175 191 9.14
2018-07-30 13F-HR Trustcore Financial Services, Llc 1,821 0 -100.00 22 0 -100.00
2018-08-14 13F-HR TRUSTMARK NATIONAL BANK TRUST DEPARTMENT 103,200 0 -100.00 1,243 0 -100.00
2018-07-26 13F-HR SignalPoint Asset Management, LLC 98,106 0 -100.00 1,181 0 -100.00
2018-08-10 13F-HR HSBC HOLDINGS PLC 53,112 0 -100.00 639 0 -100.00
2018-07-13 13F-HR BANK OF MONTREAL /CAN/ 9,265 0 -100.00 112 0 -100.00
2018-08-14 13F-HR QS Investors, LLC 606 0 -100.00 7 0 -100.00
2018-05-11 13F-HR CITIGROUP INC 1,335 1,335 0.00 17 16 -5.88
2018-08-13 13F-HR Stratos Wealth Partners, LTD. 9,970 0 -100.00 120 0 -100.00
2018-08-14 13F-HR MORGAN STANLEY 1,162,909 0 -100.00 14,002 0 -100.00
2018-08-10 13F-HR Regal Investment Advisors LLC 20,082 0 -100.00 242 0 -100.00
2018-08-13 13F-HR Advisor Group, Inc. 27,678 0 -100.00 333 0 -100.00
2018-05-11 13F-HR HSBC HOLDINGS PLC 49,395 53,112 7.53 615 639 3.90
2018-08-07 13F-HR IFP Advisors, Inc 19,746 0 -100.00 238 0 -100.00
2018-07-24 13F-HR Janney Montgomery Scott LLC 22,285 0 -100.00 268 0 -100.00
2018-08-24 13F-HR/A Mainstay Capital Management Llc /adv 2,020 0 -100.00 24 0 -100.00
2018-08-06 13F-HR NTV ASSET MANAGEMENT LLC 53,450 54,950 2.81 644 658 2.17
2018-08-14 13F-HR BANK OF AMERICA CORP /DE/ 649,364 0 -100.00 7,819 0 -100.00
2018-08-14 13F-HR GOLDMAN SACHS GROUP INC 39,484 0 -100.00 475 0 -100.00
2018-08-03 13F-HR Morningstar Investment Services LLC 397,978 0 -100.00 4,792 0 -100.00
2018-08-10 13F-HR CITIGROUP INC 1,335 0 -100.00 16 0 -100.00
2018-08-13 13F-HR B & T Capital Management DBA Alpha Capital Management 22,278 0 -100.00 268 0 -100.00
2018-08-10 13F-HR Amerivest Investment Management LLC 962,496 0 -100.00 11,588 0 -100.00
2018-08-14 13F-HR ROYAL BANK OF CANADA 23,312 0 -100.00 281 0 -100.00
2018-08-14 13F-HR COLDSTREAM CAPITAL MANAGEMENT INC 36,160 0 -100.00 435 0 -100.00
2018-08-14 13F-HR BARCLAYS PLC 14 0 -100.00 0 0
2018-07-16 13F-HR Beacon Capital Management, Inc. 750,168 0 -100.00 9,032 0 -100.00
2018-08-14 13F-HR/A CITADEL ADVISORS LLC 88,916 0 -100.00 1,071 0 -100.00
2018-08-13 13F-HR RAYMOND JAMES & ASSOCIATES 36,908 0 -100.00 444 0 -100.00
2018-08-01 13F-HR WELLS FARGO & COMPANY/MN 2,193,016 0 -100.00 26,405 0 -100.00
2018-09-18 13F-HR/A NORTHERN TRUST CORP 11,633 0 -100.00 140 0 -100.00
2018-08-15 13F-HR LADENBURG THALMANN FINANCIAL SERVICES INC 52,327 52,327 0.00 630 630 0.00
2018-08-14 13F-HR MANUFACTURERS LIFE INSURANCE COMPANY, THE 18,213 0 -100.00 219 0 -100.00
2018-08-13 13F-HR ADVANTAGE INVESTMENT MANAGEMENT, LLC 1,975 0 -100.00 24 0 -100.00
2018-08-14 13F-HR CLS Investments, LLC 18,653 0 -100.00 225 0 -100.00
2018-08-10 13F-HR ENVESTNET ASSET MANAGEMENT INC 193,984 0 -100.00 2,346 0 -100.00
2018-07-20 13F-HR Steward Partners Investment Advisory, Llc 25,136 0 -100.00 302 0 -100.00
2018-07-19 13F-HR BENJAMIN F. EDWARDS & COMPANY, INC. 25,672 0 -100.00 309 0 -100.00
2018-07-26 13F-HR Advisornet Financial, Inc 31,245 0 -100.00 376 0 -100.00
2018-07-24 13F-HR ROTHSCHILD INVESTMENT CORP /IL 14,000 0 -100.00 169 0 -100.00
2018-08-14 13F-HR Centaurus Financial, Inc. 23,160 0 -100.00 279 0 -100.00
2018-08-13 13F-HR MML INVESTORS SERVICES, LLC 18,430 0 -100.00 222 0 -100.00
2018-08-03 13F-HR Seacrest Wealth Management, Llc 371 0 -100.00 4 0 -100.00
2018-08-08 13F-HR Private Capital Group, Llc 1,357 0 -100.00 16 0 -100.00
2018-07-31 13F-HR Sheaff Brock Investment Advisors, LLC 19,099 0 -100.00 230 0 -100.00
2018-08-13 13F-HR Cardan Capital Partners, LLC 20,444 0 -100.00 246 0 -100.00
2018-08-14 13F-HR CREDIT SUISSE AG/ 80,802 0 -100.00 973 0 -100.00
2018-08-10 13F-HR Cambridge Investment Research Advisors, Inc. 14,488 0 -100.00 174 0 -100.00
2017-08-18 13F-HR WFG Advisors, LP 19,865 7,342 -63.04 626 92 -85.30
2017-01-13 13F-HR MetLife Securities, Inc 1,082 19,177 1,672.37 114 213 86.84
2018-07-31 13F-HR Commonwealth Equity Services, Llc. 27,886 0 -100.00 335 0 -100.00
2018-08-09 13F-HR PineBridge Investments, L.P. 158,800 0 -100.00 1,912 0 -100.00
2018-08-13 13F-HR Camelot Portfolios, LLC 24,458 0 -100.00 295 0 -100.00
2018-08-15 13F-HR JANE STREET GROUP, LLC 84,328 0 -100.00 1,015 0 -100.00
2018-09-20 13F-HR Rehmann Capital Advisory Group 3,325 0 -100.00 40 0 -100.00

Related Articles

DMPI: DelMar Pharmaceuticals Analysis and Research Report

5h - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

EKSO: Ekso Bionics Holdings Analysis and Research Report

2018-09-18 - Asif

Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...

CUSIP: 73935X195